Biocytogen signs antibody license agreement with Pheon Therapeutics
Biocytogen Pharmaceuticals, a global biotech firm specialising in novel antibody therapeutics, has agreed to a licensing deal with Pheon Therapeutics, an antibody-drug conjugate (ADC) developer. ... Read More
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based in Switzerland. This strategic acquisition is set ... Read More